Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 29 04:00PM ET
12.55
Dollar change
+0.27
Percentage change
2.20
%
Index- P/E- EPS (ttm)- Insider Own17.73% Shs Outstand26.88M Perf Week-1.10%
Market Cap337.34M Forward P/E- EPS next Y-3.11 Insider Trans15.17% Shs Float22.12M Perf Month-19.34%
Income- PEG- EPS next Q-0.66 Inst Own60.20% Short Float11.70% Perf Quarter-18.13%
Sales- P/S- EPS this Y71.03% Inst Trans- Short Ratio15.84 Perf Half Y-
Book/sh7.18 P/B1.75 EPS next Y-10.42% ROA- Short Interest2.59M Perf Year-
Cash/sh7.66 P/C1.64 EPS next 5Y- ROE- 52W Range11.68 - 24.00 Perf YTD-39.37%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-47.71% Beta-
Dividend TTM- Quick Ratio26.02 Sales past 5Y-50.00% Gross Margin- 52W Low7.45% ATR (14)1.03
Dividend Ex-Date- Current Ratio26.02 EPS Y/Y TTM- Oper. Margin- RSI (14)43.43 Volatility8.16% 7.91%
Employees63 Debt/Eq0.05 Sales Y/Y TTM- Profit Margin- Recom1.17 Target Price35.55
Option/ShortNo / Yes LT Debt/Eq0.05 EPS Q/Q- Payout- Rel Volume0.29 Prev Close12.28
Sales Surprise- EPS Surprise-64.50% Sales Q/Q- EarningsMay 14 AMC Avg Volume163.35K Price12.55
SMA20-8.13% SMA50-11.72% SMA200-14.89% Trades Volume47,699 Change2.20%
Date Action Analyst Rating Change Price Target Change
Feb-27-24Initiated William Blair Outperform
Feb-27-24Initiated TD Cowen Outperform
Feb-27-24Initiated Stifel Buy $32
Feb-27-24Initiated Robert W. Baird Outperform $32
Feb-27-24Initiated Jefferies Buy $33
Today 08:05AM
May-21-24 08:05AM
May-14-24 10:54PM
04:03PM
May-09-24 08:05AM
08:05AM Loading…
Apr-23-24 08:05AM
Apr-10-24 03:30PM
Apr-09-24 09:37AM
Apr-03-24 08:05AM
Mar-21-24 04:05PM
Mar-11-24 08:05AM
Mar-07-24 08:00AM
Feb-27-24 08:00AM
Feb-06-24 04:05PM
Feb-01-24 08:57PM
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Los Altos, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Smith Nicholas ConradCHIEF FINANCIAL OFFICERMar 28 '24Buy16.366,150100,62826,866Apr 01 04:15 PM
Alpha Wave Global, LP10% OwnerFeb 06 '24Buy16.00600,0009,600,0003,707,757Feb 08 04:32 PM
Savitz AdamCHIEF MEDICAL OFFICERFeb 06 '24Buy16.0017,000272,00024,851Feb 07 04:38 PM
Etkin AmitPRESIDENT AND CEOFeb 06 '24Buy16.003,12550,0001,205,465Feb 07 04:36 PM
Smith Nicholas ConradCHIEF FINANCIAL OFFICERFeb 06 '24Buy16.001,56325,0081,563Feb 07 04:40 PM